Abstract 1708P
Background
Since China implemented the regulations on adjusting the approval process of imported drugs in 2017, the integration of China into the global development of novel anticancer drugs has accelerated. The changing registration pathways for these products inspire us to present this data analysis.
Methods
Based on the review reports of approved global anticancer drugs from the database of the Center of Drug Evaluation of China, the cancer type, scope and timeline of pivotal supporting trials for each indication were extracted by the end of 2022. The distribution of registration pathways was explored using the number of indications as the key indicator.
Results
A total of 83 approved indications were retrieved. Participating in synchronous global studies (39, 47.0%) was the most common registration pathway, which was divided into dose expansion/phase II (4, 4.8%) and confirmatory studies (35, 42.2%). Launching China-dominant studies was another main pathway (35, 42.2%), including bridging (26, 31.3%) and confirmatory studies (10, 12.0%). Clinical studies in China were exempted in 15 (18.1%) indications. Multiple pathways were used to support 7 (8.4%) indications. The number of indications supported by China-dominant studies decreased from 19 (2017-2019) to 15 (2020-2022), while that of synchronous global studies increased from 15 (2017-2019) to 23 (2020-2022). Among the 9 indications for esophageal, gastric and hepatocellular cancer, eight (88.9%) were approved by global studies. The median days between China and the first global approval was 371 in indications supported by global studies, compared with 1326 in that supported by China-dominant studies.
Table: 1708P
No. of indications | ||||||||
Year | Dose-expansion/phase II | Global confirmatory studies | Synchronous global studies | Bridging studies | China-dominant confirmatory studies | China-dominant studies | Exemption of clinical studies in China | Total |
2015 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
2017 | 1 | 2 | 3 | 3 | 2 | 5 | 1 | 7 |
2018 | 0 | 5 | 5 | 5 | 2 | 6 | 0 | 10 |
2019 | 2 | 5 | 7 | 5 | 3 | 8 | 4 | 18 |
2020 | 0 | 9 | 9 | 4 | 1 | 5 | 5 | 19 |
2021 | 0 | 8 | 8 | 4 | 2 | 6 | 4 | 17 |
2022 | 1 | 5 | 6 | 4 | 0 | 4 | 1 | 11 |
Total (%) | 4(4.8%) | 35(42.2%) | 39(47.0%) | 26(31.3%) | 10(12.0%) | 35(42.2%) | 15(18.1%) | 83(100.0%) |
Median days between China and global approval | 1399 | 365 | 371 | 1230 | 2082 | 1326 | 2064 | 1045 |
Conclusions
Participating in synchronous global studies is the most common and time-saving registration pathway in China for globally developed novel anticancer drugs in recent years, especially for Chinese high-prevalent cancers. Efforts should be made to help China join more global early-phase studies in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2375P - Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Presenter: Zhou Tong
Session: Poster session 23
2376P - Pembrolizumab monotherapy following tri-modality treatment for selected patients with muscle-invasive bladder cancer
Presenter: Shang Bin Qin
Session: Poster session 23
2378P - Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment
Presenter: Vadim Koshkin
Session: Poster session 23
2379P - AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Presenter: Philippe Barthélémy
Session: Poster session 23